Clinical trials: Residual Disease
Sensorineural Hearing Loss
Immunity After Cochlear Implantation and Perilymph Molecular Profiles in Sensorineural Hearing Loss
Many patients receiving cochlear implant (CI) have some residual hearing prior to implantation surgery. However, approximately one third of them will lose it in next 6 months after cochlear implantation.
- Trial name
- PERILOTO (NCT05670158)
- Testing
- Blood sampling, Perilymph sampling
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Montpellier
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Obesity
Impact of Increased Tidal Volumes on Oxygenation and Cardiac Output
General anaesthesia impairs respiratory function in overweight patients. The investigators wanted to compare arterial concentration of sevoflurane and oxygen in overweight patients ventilated with increased tidal volume, or…
- Trial name
- NCT01343017
- Testing
- Ventilatory pattern
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Region Skane
T-cell Acute Lymphoblastic Leukemia
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Trial name
- NCT05289687
- Testing
- Daratumumab / Hyaluronidase Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
RATIONALE: Diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia.
- Trial name
- NCT00005619
- Testing
- polymerase chain reaction, flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Northwestern University
Obesity
Impact of the Residual Gastric Volume in Laparoscopic Sleeve Gastrectomy's Failure
Obesity is a worldwide health problematic whose incidence is increasing especially in developed countries. The surgical management of this illness consists in different techniques such as Laparoscopic Sleeve Gastrectomy but this…
- Trial name
- GASTROMANCH (NCT01539967)
- Testing
- Laparoscopic Sleeve Gastrectomy
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Multiple Myeloma
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance…
- Trial name
- AURIGA (NCT03901963)
- Testing
- Daratumumab, Lenalidomide
- Where
- 73 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer, Melanoma
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular…
- Conditions
- Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NIP IT! (NCT05196087)
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University Health Network, Toronto
Triple-Negative Invasive Breast Carcinoma, Residual Tumor
Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. Its incidence is approximately 180,000 cases per year.
- Trial name
- NCT02670109
- Testing
- Carmustine, Cyclophosphamide, Carboplatin
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Infection, Surgical Site
Use of Real-time Fluorescence Imaging in Diabetic Foot Ulcers: the Impact of Colonization
The study evaluates the efficacy of fluorescence-guided de-colonization in patients with non-infected diabetic foot ulcers. The efficacy will also be compared between those who used artificial dermis and split-thickness skin…
- Trial name
- NCT05873049
- Testing
- MolecuLight
- Where
- Taiwan
- Volunteers
- 210 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
HIV-1-infection, Methamphetamine-dependence
Effect of Methamphetamine on Residual Latent HIV Disease Study
The most commonly used illicit stimulant in HIV-infected individuals is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation.
- Trial name
- EMRLHD (NCT03825536)
- Testing
- Oral Methamphetamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Chronic Subdural Hematoma
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma
Chronic subdural hematoma (CSDH) is a common disease after minor head trauma, especially in elderly patients. This medical condition is characterized by blood collection in the subdural space, which can result in severe…
- Trial name
- TRACE (NCT03280212)
- Testing
- Tranexamic Acid 500 MG
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Multiple Myeloma, Myeloma-Associated Amyloidosis
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
This phase II clinical trial studies the addition of selinexor to lenalidomide in patients with multiple myeloma following transplant.
- Trial name
- NCT05820763
- Testing
- Selinexor, Lenalidomide, Dexamethasone
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia (AML), Minimal Residual Disease
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
This is a phase I / II study. The purposes of this study are to: 1) find out what effects, good and/or bad, the combination of the experimental drug avelumab and the drug azacitidine has on people with AML and MRD, and 2) test if…
- Trial name
- NCT03699384
- Testing
- Azacitidine, Avelumab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Pediatric
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
A retrospective analysis to investigate pediatric B-cell acute lymphoblastic leukemia patients who were treated with blinatumomab for consolidation, and who were detected as minimal residual disease (MRD) positive by next…
- Trial name
- NCT05837689
- Testing
- Blinatumomab
- Volunteers
- 20 people
- Sponsor
- Xiaojun Xu
Ovarian Cancer
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003733
- Testing
- carboplatin, paclitaxel, topotecan hydrochloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- SmithKline Beecham
Muscle Relaxants
The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio
evaluate the degree of association, and the predictive accuracy of the REPS (as a predictive tool) compared with the TOFr as a quantitative assessment tool for (rNMB) in surgical patients in the early postoperative phase.
- Trial name
- NCT06899048
- Testing
- residual neuromuscular block risk prediction score
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- Assiut University
Chronic Kidney Failure
Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function
This is a two phase study. The first part will take place at the National Institute of Cardiology in Mexico, the second phase will be made in collaboration with the University of California San Diego and University of Minnesota.
- Trial name
- NCT05105009
- Testing
- Furosemide Injection, Creatinine Powder, Iohexol
- Where
- Mexico
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Study Design: This is a two-stage Phase II trial investigating the efficacy of Clofarabine, Cyclophosphamide and Etoposide in acute leukemia patients with detectable minimal residual disease (MRD) prior to allo-HCT.
- Trial name
- NCT01677949
- Testing
- Clofarabine, Etoposide, Cyclophosphamide
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Myelodysplastic Syndromes
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- NCT02477878
- Testing
- BPX-501, Rimiducid
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Bellicum Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.